ADVANZ PHARMA acquires the rights to Nootropil® and Atarax® from UCB for Europe and selected countries in LATAM and APAC

Atarax® (hydroxyzine dihydrochloride) and Nootropil® (piracetam) are sold in more than 30 countries across Europe, LATAM and APACThe acquisition leverages ADVANZ PHARMA’s commercial and medical footprint in Europe, as well as its global distribution partner networkThe acquisition further strengthens ADVANZ PHARMA’s global specialty brands portfolio London, UK – 05/11/2024: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, Canada, and Australia, today announced it expands its specialty brands portfolio with the closing of the acquisition of the rights to Atarax® and Nootropil® from UCB. ADVANZ PHARMA continues leveraging its commercial footprint and global partner network to bring specialty medicines to patients worldwide. Atarax® is an antihistamine, which is indicated for the symptomatic treatment of anxiety in adults, as well as for the treatment of pruritis in adults and children.* Nootropil® is a nootropic agent. It is indicated for psycho-organic syndrome, vertigo and myoclonus in adults, as well as for dyslexia in children in certain territories.* *Indications vary by market, strength, and form. For local indications please check the local approved label. About ADVANZ PHARMA Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. For more information, please visit our Website or LinkedIn. For media inquiries, please contact: Courtney Baines ADVANZ PHARMA Tel: +44 7776 516979 Email: [email protected]

The release as fetched from its publisher. advanzpharma.com ↗